Abstract: Ｏｂｊｅｃｔｉｖｅ：To observe the efficacy and side effects of rituximab(RTX) in the treatment of cryoglobulinaemic membranoproliferative glomerulonephritis(MPGN).
Ｍｅｔｈｏｄｏｌｏｇｙ：Eight patients with biopsy proven cryoglobulinaemic MPGN were enrolled in this study. RTX was given intravenously at 375 mg/m2.
Ｒｅｓｕｌｔｓ：Four patients were associated with HBV infection . All patients were treated with glucocorticosteroid therapy, combined with tacrolimus in 2 cases. Entecavir were prescribed to 4 patients with HBV infection. With a median followup of 35(12～40) months,4 cases achieved complete remission,2 cases achieved partial remission and 2 cases failed to respond. No acute or chronic serious adverse reactions were observed during RTX treatment.
Ｃｏｎｃｌｕｓｉｏｎ：RTX combined with glucocorticosteroid can be an effective and safe selection in patients with cryoglobulinaemic MPGN，which may be worthy of further study.

Key words: Rituximab, cryoglobulinaemia, membranoproliferative glomerulonephritis, hepatitis B virus infection